Back to top
Top
U.S. flag

An official website of the United States government

Dot gov

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Https

Secure .gov websites use HTTPS
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

eCQMs in Advancing Care for Heart Disease (MVP ID: G0055)

Year CMS eCQM ID Measure Name
2024 CMS2v13 Preventive Care and Screening: Screening for Depression and Follow-Up Plan
2025 CMS2v14 Preventive Care and Screening: Screening for Depression and Follow-Up Plan
2026 CMS2v15 Preventive Care and Screening: Screening for Depression and Follow-Up Plan
2024 CMS69v12 Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan
2025 CMS69v13 Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan
2026 CMS69v14 Preventive Care and Screening Body Mass Index (BMI) Screening and Follow Up Plan
2024 CMS90v13 Functional Status Assessments for Heart Failure
2025 CMS90v14 Functional Status Assessments for Heart Failure
2026 CMS90v15 Functional Status Assessments for Heart Failure
2024 CMS135v12 Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) or Angiotensin Receptor-Neprilysin Inhibitor (ARNI) Therapy for Left Ventricular Systolic Dysfunction (LVSD)
2025 CMS135v13 Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) or Angiotensin Receptor-Neprilysin Inhibitor (ARNI) Therapy for Left Ventricular Systolic Dysfunction (LVSD)
2026 CMS135v14 Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) or Angiotensin Receptor-Neprilysin Inhibitor (ARNI) Therapy for Left Ventricular Systolic Dysfunction (LVSD)
2024 CMS144v12 Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)
2025 CMS144v13 Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)
2026 CMS144v14 Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)
2024 CMS145v12 Coronary Artery Disease (CAD): Beta-Blocker Therapy-Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF) less than or equal to 40%
2025 CMS145v13 Coronary Artery Disease (CAD): Beta-Blocker Therapy-Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF less than or equal to 40%)
2026 CMS145v14 Coronary Artery Disease (CAD): Beta-Blocker Therapy-Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF less than or equal to 40%)
2024 CMS156v12 Use of High-Risk Medications in Older Adults
2025 CMS156v13 Use of High-Risk Medications in Older Adults

We want your feedback

For technical questions about eCQMs, please log in to the ONC Project Tracking System, specifically the eCQM Issue Tracker.

eCQI Resource Center Feedback pertains to:
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.